Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-07-02FDA Approved: DECITABINE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals’ decitabine as an Original Application (ANDA), providing a generic injectable option. The approval cov…
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma [Phase 2]
Phase 2 trial evaluating CD8+ memory T-cells as consolidative therapy after donor non-myeloablative hematopoietic cell transplant in leukemi…
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine [Phase 1, Phase 2]
Phase II extension study of oral rigosertib in combination with azacitidine in myelodysplastic syndrome and related conditions has completed…
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure [Phase 2]
Phase 2 trial evaluating omacetaxine in intermediate-1 and higher risk myelodysplastic syndrome after failure of hypomethylating therapy; st…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Unrelated Umbilical Cord Blood (UBC)Transplantation [NA]
Clinical trial update for unrelated umbilical cord blood transplantation; the study is completed with results posted in 2021.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS [Phase 2]
Phase II trial update for DAC in relapsed/refractory and elderly patients with acute myeloid leukemia and myelodysplastic syndrome.
-
CLINICAL_TRIALS trial_result · 2021-05-13Clinical Trial Update: A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase I-II open-label trial of TL32711 in acute myeloid leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia; study terminat…
-
CLINICAL_TRIALS trial_result · 2021-05-04Clinical Trial Update: DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 [Phase 1, Phase 2]
Clinical trial update for DEPLETHINK (NKR-2) reporting Phase 1/Phase 2 results in AML and MDS; trial status completed.
-
CLINICAL_TRIALS withdrawal · 2021-04-27Clinical Trial Update: Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT [Phase 3]
Phase 3 randomized trial evaluating standard of care with or without atorvastatin for prevention of graft-versus-host disease in matched unr…
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS [Phase 2]
Phase 2 clinical trial evaluating Vidaza (azacitidine) and valproic acid after allogeneic transplant in high-risk AML and MDS.
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Busulfan and Cyclophosphamide Followed By ALLO BMT [NA]
Clinical trial update for busulfan and cyclophosphamide followed by allogeneic stem cell transplant in acute leukemias; study is terminated …
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: Early Palliative Care for Patients With Haematological Malignancies [Phase 3]
Phase 3 clinical trial update on early palliative care for patients with hematologic malignancies including acute myeloid leukemia and myelo…
-
CLINICAL_TRIALS trial_result · 2021-03-22Clinical Trial Update: Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms [Phase 2]
Phase 2 trial evaluating early allogeneic hematopoietic cell transplantation for patients with relapsed or refractory high-grade myeloid neo…
-
CLINICAL_TRIALS trial_result · 2021-03-18Clinical Trial Update: The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients [Phase 2]
Phase II randomized trial evaluating rapid haploidentical plus unrelated cord donor search versus matched unrelated donor search for AML and…
-
FDA approval · 2021-03-17FDA Approved: DEFERASOROX — Original Application (Novadoz Pharmaceuticals LLC)
The FDA granted approval for the original ANDA application of Deferasorox (deferasirox) by Novadoz Pharmaceuticals LLC as a generic product.…
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients [Phase 1]
A Phase 1 trial evaluating the combination of glasdegib (PF-04449913) with azacitidine in untreated myelodysplastic syndrome, acute myeloid …
-
CLINICAL_TRIALS trial_result · 2021-02-26Clinical Trial Update: Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial evaluating treosulfan, fludarabine phosphate, and total-body irradiation as conditioning before donor stem cell transplant in …
-
CLINICAL_TRIALS trial_result · 2021-02-25Clinical Trial Update: Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms [Phase 1, Phase 2]
Phase 1b/2 trial assessing APR-246 plus azacitidine in TP53-mutant myeloid neoplasms completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-01-26Clinical Trial Update: Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial evaluating busulfan, fludarabine, and clofarabine conditioning followed by allogeneic stem cell transplantation in pa…
-
FDA approval · 2021-01-25FDA Approved: DECITABINE — Supplemental Application (Novadoz Pharmaceuticals LLC)
FDA approved a supplemental application for decitabine (generic) submitted by Novadoz Pharmaceuticals LLC. The approval relates to the ANDA …
-
CLINICAL_TRIALS trial_result · 2021-01-19Clinical Trial Update: IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome [Phase 3]
Phase 3 trial evaluating intravenous busulfan with allogeneic hematopoietic stem cell transplant for patients with myelodysplastic syndrome …
-
CLINICAL_TRIALS trial_result · 2021-01-19Clinical Trial Update: G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT [Phase 2, Phase 3]
A Phase 2/Phase 3 trial compares G-CSF+DAC+BUCY versus G-CSF+DAC+BF conditioning regimens for RAEB-1/REAB-2 and AML secondary to MDS in pati…
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor [Phase 2, Phase 3]
Clinical trial update on ATIR donor lymphocyte preparation for haploidentical stem cell transplantation; study terminated with posted result…
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor [Phase 2]
Phase 2 trial evaluating two doses of ATIR101 (T-lymphocyte enriched, host alloreactive T-cell depleted) in hematologic malignancy patients …
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor [Phase 2]
Phase 2 trial update on ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with hematologic malignancies p…